PBS updates

Opdivo (Nivolumab)

nivolumab 100 mg/10 mL injection, 10 mL vial · INJECTION · PBS code 14233D

STREAMLINED

What it costs

AU$1972.83 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2024-08-01.
  • • Repeats: 2.
  • • PBS program: IP.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Resectable non-small cell lung cancer (NSCLC)


The condition must be at least one of: (i) node positive, (ii) at least 4 cm in size; AND

The treatment must be for neoadjuvant use in a patient preparing for surgical resection; AND

Patient must have a WHO performance status of 0 or 1; AND

The treatment must be in combination with platinum-based chemotherapy; AND

Patient must not be undergoing treatment with more than 3 PBS-subsidised doses of this drug per lifetime for this indication.

In non-squamous type NSCLC where any of the following is known to be present, this drug must not be a PBS benefit: (i) activating epidermal growth factor receptor (EGFR) gene mutation, (ii) anaplastic lymphoma kinase (ALK) gene rearrangement.

Sponsor: Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.